{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:33:29Z","timestamp":1791196409357,"version":"4.1.0"},"reference-count":166,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.2217\/imt.10.67","type":"journal-article","created":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T07:24:57Z","timestamp":1290410697000},"page":"817-833","source":"Crossref","is-referenced-by-count":196,"title":["Anti-TNF-\u03b1 Agents in the Treatment of Immune-Mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls"],"prefix":"10.1080","volume":"2","author":[{"given":"L\u00e9ia CR","family":"Silva","sequence":"first","affiliation":[{"name":"Laboratory of Dermatology &amp; Immunodeficiencies, Dermatology Division, Clinics Hospital, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciena CM","family":"Ortigosa","sequence":"additional","affiliation":[{"name":"Laboratory of Dermatology &amp; Immunodeficiencies, Dermatology Division, Clinics Hospital, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Benard","sequence":"additional","affiliation":[{"name":"Laboratory of Dermatology &amp; Immunodeficiencies, Dermatology Division, Clinics Hospital, S\u00e3o Paulo, Brazil"},{"name":"Laboratory of Medical Mycology, Tropical Medicine Institute, University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil: R Dr Eneas de Carvalho Aguiar 470, Instituto de Medicina Tropical (IMT), Cerqueira Cesar, S\u00e3o Paulo, SP, 05403 903, Brazil. Tel.:  Fax:"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2010,11,22]]},"reference":[{"key":"e_1_3_2_2_1_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.72.9.3666"},{"key":"e_1_3_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342607"},{"key":"e_1_3_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(02)00019-9"},{"key":"e_1_3_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00022-4"},{"key":"e_1_3_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(01)00335-9"},{"key":"e_1_3_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90106-L"},{"key":"e_1_3_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_3_2_2_8_1","unstructured":"Remicade\u00ae (infliximab) prescribing information. Centocor Inc. PA USA (2006)."},{"key":"e_1_3_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.08.013"},{"key":"e_1_3_2_2_10_1","unstructured":"Enbrel\u00ae (etanercept) prescribing information. Immunex Corp. CA USA (2007)."},{"key":"e_1_3_2_2_11_1","unstructured":"Humira (adalimumab) prescribing information. Abbott Laboratories IL USA (2007)."},{"key":"e_1_3_2_2_12_1","first-page":"S10","article-title":"Why do anti-tumor necrosis factor antibodies work in Crohn\u2018s disease?","volume":"4","author":"Sands BE","year":"2004","unstructured":"Sands BE : Why do anti-tumor necrosis factor antibodies work in Crohn\u2018s disease?Rev. Gastroenterol. Disord.4(Suppl. 3) , S10\u2013S17 (2004).","journal-title":"Rev. Gastroenterol. Disord."},{"key":"e_1_3_2_2_13_1","first-page":"31","article-title":"Effects of infliximab treatment on rheumatoid synovial tissue.","volume":"74","author":"Tak PP","year":"2005","unstructured":"Tak PP : Effects of infliximab treatment on rheumatoid synovial tissue.J. Rheumatol. Suppl.74 , 31\u201334 (2005).","journal-title":"J. Rheumatol. Suppl."},{"key":"e_1_3_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11098"},{"key":"e_1_3_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20764"},{"key":"e_1_3_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02859.x"},{"key":"e_1_3_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.206"},{"key":"e_1_3_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.53.1.70"},{"key":"e_1_3_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28702"},{"key":"e_1_3_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1182"},{"key":"e_1_3_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07078.x"},{"key":"e_1_3_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.004"},{"issue":"9","key":"e_1_3_2_2_23_1","first-page":"890","article-title":"Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.","volume":"5","author":"Malaviya R","year":"2006","unstructured":"Malaviya R , SunY, TanJK et al.: Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.J. Drugs Dermatol.5(9) , 890\u2013893 (2006).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00205.x"},{"key":"e_1_3_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.3.1521"},{"key":"e_1_3_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.723"},{"key":"e_1_3_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F"},{"key":"e_1_3_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh178"},{"key":"e_1_3_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10847"},{"key":"e_1_3_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.561"},{"key":"e_1_3_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.1.36"},{"key":"e_1_3_2_2_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.11.968"},{"key":"e_1_3_2_2_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2721"},{"key":"e_1_3_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L"},{"key":"e_1_3_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.443"},{"key":"e_1_3_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.01.038"},{"key":"e_1_3_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.012617"},{"key":"e_1_3_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1740-2557-3-5"},{"key":"e_1_3_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C"},{"key":"e_1_3_2_2_40_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.51.1.207"},{"key":"e_1_3_2_2_41_1","unstructured":"Firestein GS : Etiology and pathogenesis of rheumatoid arthritis. In: Textbook of Rheumatology (5th Edition). Kelley WN Harris ED Jr Ruddy S Sledge CB (Eds). WB Saunders PA USA 851\u2013897 (1997)."},{"key":"e_1_3_2_2_42_1","first-page":"1599","article-title":"Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.","volume":"23","author":"Ishiguro N","year":"1996","unstructured":"Ishiguro N , ItoT, ObataK et al.: Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.J. Rheumatol.23 , 1599\u20131604 (1996).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_2_43_1","first-page":"2329","article-title":"Elevated plasma stromelysin levels in arthritis.","volume":"21","author":"Zucker S","year":"1994","unstructured":"Zucker S , LysikRM, ZarrabiMH et al.: Elevated plasma stromelysin levels in arthritis.J. Rheumatol.21 , 2329\u20132333 (1994).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_2_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.5.484"},{"key":"e_1_3_2_2_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.6.643"},{"key":"e_1_3_2_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21426"},{"key":"e_1_3_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2003.08.015"},{"key":"e_1_3_2_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390702"},{"key":"e_1_3_2_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390703"},{"issue":"1","key":"e_1_3_2_2_50_1","first-page":"36","article-title":"Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.","volume":"52","author":"Klimiuk PA","year":"2004","unstructured":"Klimiuk PA , SierakowskiS, DomyslawskaI et al.: Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.Arch. Immunol. Ther. Exp. (Warsz).52(1) , 36\u201342 (2004).","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)."},{"key":"e_1_3_2_2_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018085"},{"key":"e_1_3_2_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.01.003"},{"key":"e_1_3_2_2_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_3_2_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4567"},{"key":"e_1_3_2_2_55_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040165"},{"key":"e_1_3_2_2_56_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061531"},{"key":"e_1_3_2_2_57_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.418"},{"key":"e_1_3_2_2_58_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1995.0029"},{"issue":"4","key":"e_1_3_2_2_59_1","first-page":"A697","article-title":"Neutralization of soluble and membrane tumor necrosis factor-\u03b1 (TNF-\u03b1) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-\u03b1 receptor-specific bioassays,","volume":"130","author":"Gramlick A","year":"2006","unstructured":"Gramlick A , FossatiG, NesbittAM et al.: Neutralization of soluble and membrane tumor necrosis factor-\u03b1 (TNF-\u03b1) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-\u03b1 receptor-specific bioassays,Gastroenterology130(4) , A697 (2006).","journal-title":"Gastroenterology"},{"key":"e_1_3_2_2_60_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-200609001-01115"},{"key":"e_1_3_2_2_61_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38482"},{"key":"e_1_3_2_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2004.03.011"},{"key":"e_1_3_2_2_63_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.130"},{"key":"e_1_3_2_2_64_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.060"},{"key":"e_1_3_2_2_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"e_1_3_2_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh514"},{"key":"e_1_3_2_2_67_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/201430"},{"key":"e_1_3_2_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.001"},{"key":"e_1_3_2_2_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-1-79"},{"key":"e_1_3_2_2_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0165-9"},{"key":"e_1_3_2_2_71_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221307779815039"},{"key":"e_1_3_2_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0948-3"},{"key":"e_1_3_2_2_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20536"},{"key":"e_1_3_2_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24283"},{"key":"e_1_3_2_2_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1067-x"},{"key":"e_1_3_2_2_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken469"},{"key":"e_1_3_2_2_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540701877320"},{"key":"e_1_3_2_2_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0042-4"},{"key":"e_1_3_2_2_79_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.006809-0"},{"key":"e_1_3_2_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.04.010"},{"key":"e_1_3_2_2_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23705"},{"key":"e_1_3_2_2_82_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1309.070070"},{"issue":"6","key":"e_1_3_2_2_83_1","first-page":"649","article-title":"Update on the British Society for Rheumatology guidelines for prescribing TNF-\u03b1 blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).","volume":"45","author":"Ledingham J","year":"2006","unstructured":"Ledingham J , DeightonC: Update on the British Society for Rheumatology guidelines for prescribing TNF-\u03b1 blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).Rheumatology (Oxford)45(6) , 649\u2013652 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_3_2_2_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23815"},{"key":"e_1_3_2_2_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20882"},{"key":"e_1_3_2_2_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.161638"},{"key":"e_1_3_2_2_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep1119"},{"key":"e_1_3_2_2_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.015"},{"key":"e_1_3_2_2_89_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2006.039"},{"issue":"5","key":"e_1_3_2_2_90_1","first-page":"883","article-title":"Risks and benefits of tumor necrosis factor-\u03b1 inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.","volume":"35","author":"Saad AA","year":"2008","unstructured":"Saad AA , SymmonsDP, NoycePR, AshcroftDM: Risks and benefits of tumor necrosis factor-\u03b1 inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.J. Rheumatol.35(5) , 883\u2013890 (2008).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_2_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0775-y"},{"issue":"3","key":"e_1_3_2_2_92_1","first-page":"235","article-title":"[Leishmaniasis in rheumatoid arthritis.]","volume":"59","author":"Pizzorni C","year":"2007","unstructured":"Pizzorni C , SecchiME, CutoloM: [Leishmaniasis in rheumatoid arthritis.]Reumatismo59(3) , 235\u2013239 (2007).","journal-title":"Reumatismo"},{"key":"e_1_3_2_2_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_3_2_2_94_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0540"},{"issue":"20","key":"e_1_3_2_2_95_1","first-page":"799","article-title":"[Fatal phenmococcal sepsis in patient with hidradenitis suppurative treated with inflixumeb.]","volume":"131","author":"Ben\u00edtez-Mac\u00edas JF","year":"2008","unstructured":"Ben\u00edtez-Mac\u00edas JF , Garc\u00eda-GilD, Brun-RomeroFM: [Fatal phenmococcal sepsis in patient with hidradenitis suppurative treated with inflixumeb.]Med. Clin. (Barc.)131(20) , 799 (2008).","journal-title":"Med. Clin. (Barc.)"},{"key":"e_1_3_2_2_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0695-4"},{"issue":"2","key":"e_1_3_2_2_97_1","first-page":"175","article-title":"Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.","volume":"8","author":"Darabi K","year":"2009","unstructured":"Darabi K , JaiswalR, HostetlerS, BechtelM, ZirwasM: Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.J. Drugs Dermatol.8(2) , 175\u2013178 (2009).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_2_2_98_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/814698"},{"key":"e_1_3_2_2_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"e_1_3_2_2_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31819bca9e"},{"key":"e_1_3_2_2_101_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_3_2_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.011"},{"key":"e_1_3_2_2_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08851.x"},{"key":"e_1_3_2_2_104_1","doi-asserted-by":"publisher","DOI":"10.1159\/000149311"},{"key":"e_1_3_2_2_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-2-282"},{"key":"e_1_3_2_2_106_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0053-0"},{"key":"e_1_3_2_2_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2165-x"},{"key":"e_1_3_2_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.11.002"},{"issue":"12","key":"e_1_3_2_2_109_1","first-page":"1137","article-title":"Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.","volume":"7","author":"Menter A","year":"2008","unstructured":"Menter A , ReichK, GottliebAB et al.: Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.J. Drugs Dermatol.7(12) , 1137\u20131146 (2008).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_2_2_110_1","unstructured":"Callen JP : Immunomodulators. In: Dermatology (2nd Edition). Bologna J Jorizzo JL Rapini RP (Eds). Mosby UK 1973\u20131990 (2008)."},{"key":"e_1_3_2_2_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-119974"},{"key":"e_1_3_2_2_112_1","doi-asserted-by":"publisher","DOI":"10.2165\/0002018-200831120-00009"},{"key":"e_1_3_2_2_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181957a11"},{"key":"e_1_3_2_2_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256596"},{"key":"e_1_3_2_2_115_1","doi-asserted-by":"publisher","DOI":"10.1159\/000150603"},{"key":"e_1_3_2_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.042"},{"key":"e_1_3_2_2_117_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-3-13"},{"key":"e_1_3_2_2_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0391-9"},{"key":"e_1_3_2_2_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-009-0011-z"},{"key":"e_1_3_2_2_120_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1626-1-287"},{"key":"e_1_3_2_2_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31818aedb4"},{"key":"e_1_3_2_2_122_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0062-z"},{"key":"e_1_3_2_2_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1626-1-364"},{"key":"e_1_3_2_2_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21051"},{"key":"e_1_3_2_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.10.002"},{"key":"e_1_3_2_2_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20924"},{"key":"e_1_3_2_2_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802136164"},{"issue":"3","key":"e_1_3_2_2_128_1","first-page":"401","article-title":"Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-\u03b1 blockers.","volume":"26","author":"Gonnet-Gracia C","year":"2008","unstructured":"Gonnet-Gracia C , BarnetcheT, RichezC, BlancoP, DehaisJ, SchaeverbekeT: Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-\u03b1 blockers.Clin. Exp. Rheumatol.26(3) , 401\u2013407 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_2_129_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307088291"},{"issue":"6","key":"e_1_3_2_2_130_1","first-page":"1116","article-title":"Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab.","volume":"26","author":"Mounach A","year":"2008","unstructured":"Mounach A , GhaziM, NouijaiA et al.: Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab.Clin. Exp. Rheumatol.26(6) , 1116\u20131118 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_2_131_1","first-page":"363","article-title":"Lupus like syndrome induced by treatment with anti TNF\u03b1 (infliximab): report of three cases.","volume":"99","author":"Benucci M","year":"2008","unstructured":"Benucci M , NenciG, CappellettiC, ManfrediM: Lupus like syndrome induced by treatment with anti TNF\u03b1 (infliximab): report of three cases.Recenti. Prog. Med.99(7\u20138) , 363\u2013366 (2008).","journal-title":"Recenti. Prog. Med."},{"key":"e_1_3_2_2_132_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318190dd88"},{"key":"e_1_3_2_2_133_1","doi-asserted-by":"publisher","DOI":"10.5070\/D33D29C129"},{"key":"e_1_3_2_2_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20450"},{"issue":"3","key":"e_1_3_2_2_135_1","first-page":"175","article-title":"[Infliximab-induced pustular psoriasis in a patient with Crohn\u2018s disease.]","volume":"32","author":"Monteagudo S\u00e1nchez B","year":"2009","unstructured":"Monteagudo S\u00e1nchez B , CabanillasM, Ortiz-S, Gallego-OjeaJC: [Infliximab-induced pustular psoriasis in a patient with Crohn\u2018s disease.]Gastroenterol. Hepatol.32(3) , 175\u2013176 (2009).","journal-title":"Gastroenterol. Hepatol."},{"key":"e_1_3_2_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.08.009"},{"issue":"3","key":"e_1_3_2_2_137_1","first-page":"792","article-title":"First case report of adalimumab-induced psoriasis in Crohn\u2018s disease.","volume":"104","author":"Harris MD","year":"2009","unstructured":"Harris MD , RichardsR: First case report of adalimumab-induced psoriasis in Crohn\u2018s disease.Am. J. Gastroenterol.104(3) , 792\u2013793 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_2_2_138_1","doi-asserted-by":"publisher","DOI":"10.5070\/D31ZH0D26Q"},{"key":"e_1_3_2_2_139_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087288"},{"key":"e_1_3_2_2_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23835"},{"issue":"1","key":"e_1_3_2_2_141_1","first-page":"50","article-title":"Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept.","volume":"83","author":"Levine SD","year":"2009","unstructured":"Levine SD , RobinsonM, HondaK, NedorostS: Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept.Cutis83(1) , 50 (2009).","journal-title":"Cutis"},{"key":"e_1_3_2_2_142_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.198"},{"issue":"6","key":"e_1_3_2_2_143_1","first-page":"693","article-title":"Cutaneous adverse effects of biological therapies for psoriasis.","volume":"18","author":"Ro\u00e9 E","year":"2008","unstructured":"Ro\u00e9 E , PuigL, CorellaF, Garc\u00eda-NavarroX, AlomarA: Cutaneous adverse effects of biological therapies for psoriasis.Eur. J. Dermatol.18(6) , 693\u2013699 (2008).","journal-title":"Eur. J. Dermatol."},{"key":"e_1_3_2_2_144_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1015-9"},{"key":"e_1_3_2_2_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2008.01.011"},{"issue":"1","key":"e_1_3_2_2_146_1","first-page":"200","article-title":"Severe neutrophilia induced by infliximab for psoriasis.","volume":"158","author":"de Oliveira JP","year":"2008","unstructured":"de Oliveira JP , LevyA, MorelP, GuibalF: Severe neutrophilia induced by infliximab for psoriasis.Br. J. Dermatol.158(1) , 200\u2013201 (2008).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_2_2_147_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP70240"},{"issue":"1","key":"e_1_3_2_2_148_1","first-page":"61","article-title":"Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report.","volume":"60","author":"Portuesi MG","year":"2008","unstructured":"Portuesi MG , PerosaP: Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report.Reumatismo60(1) , 61\u201363 (2008).","journal-title":"Reumatismo"},{"key":"e_1_3_2_2_149_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080521"},{"key":"e_1_3_2_2_150_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318188b1df"},{"key":"e_1_3_2_2_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1130-6343(08)75939-7"},{"key":"e_1_3_2_2_152_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2008.01490.x"},{"issue":"10","key":"e_1_3_2_2_153_1","first-page":"1958","article-title":"Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis.","volume":"35","author":"Lazzerini PE","year":"2008","unstructured":"Lazzerini PE , AcampaM, HammoudM et al.: Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis.J. Rheumatol.35(10) , 1958\u20131965 (2008).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_2_154_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K07E-043"},{"key":"e_1_3_2_2_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20270"},{"key":"e_1_3_2_2_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-2896(08)70454-X"},{"key":"e_1_3_2_2_157_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.086512"},{"key":"e_1_3_2_2_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2008.01.003"},{"key":"e_1_3_2_2_159_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282f376ac"},{"key":"e_1_3_2_2_160_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08188.x"},{"key":"e_1_3_2_2_161_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590903048909"},{"key":"e_1_3_2_2_162_1","first-page":"14","article-title":"The status of biologic therapies in the treatment of moderate to severe psoriasis.","volume":"84","author":"Menter A","year":"2009","unstructured":"Menter A : The status of biologic therapies in the treatment of moderate to severe psoriasis.Cutis84(Suppl. 4) , 14\u201324 (2009).","journal-title":"Cutis"},{"key":"e_1_3_2_2_163_1","first-page":"749","article-title":"[The immunomodulatory biotherapies of the future: what perspectives?].","volume":"38","author":"Arnauld L","year":"2009","unstructured":"Arnauld L , HarocheJ, PietteJC, AmouraZ: [The immunomodulatory biotherapies of the future: what perspectives?].Presse Med.38 , 749\u2013760 (2009).","journal-title":"Presse Med."},{"key":"e_1_3_2_2_164_1","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et disease with refractory uveoretinitis.","volume":"31","author":"Ohno S","year":"2004","unstructured":"Ohno S , NakamuraS, HoriS et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et disease with refractory uveoretinitis.J. Rheumatol.31 , 1362\u20131368 (2004).","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_2_165_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.158840"},{"key":"e_1_3_2_2_166_1","doi-asserted-by":"publisher","DOI":"10.1086\/649553"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.10.67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:59:31Z","timestamp":1715965171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.10.67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":166,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.2217\/imt.10.67"],"URL":"https:\/\/doi.org\/10.2217\/imt.10.67","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}